Disc Medicine FY2025 EPS Estimate Lifted by Leerink Partnrs

Disc Medicine, Inc. (NASDAQ:IRON) – Equities research analysts at Leerink Partnrs lifted their FY2025 earnings per share estimates for shares of Disc Medicine in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($5.33) per share for the year, up from their prior forecast of ($5.75). The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Leerink Partnrs also issued estimates for Disc Medicine’s FY2026 earnings at ($7.69) EPS, FY2027 earnings at ($8.80) EPS, FY2028 earnings at ($7.74) EPS and FY2029 earnings at ($6.31) EPS.

Other equities research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $118.00 price target on shares of Disc Medicine in a report on Tuesday, January 21st. Scotiabank lifted their target price on Disc Medicine from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research note on Wednesday, January 22nd. Jefferies Financial Group began coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 target price for the company. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective on the stock in a research note on Tuesday, November 5th. Finally, Stifel Nicolaus upped their price objective on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a report on Friday, January 24th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $88.90.

Disc Medicine Stock Down 1.2 %

Shares of NASDAQ:IRON opened at $54.07 on Monday. The company’s 50-day moving average price is $60.75 and its 200 day moving average price is $54.64. The company has a market cap of $1.61 billion, a PE ratio of -13.59 and a beta of 0.73. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $77.60.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.15.

Insider Buying and Selling

In other news, Director William Richard White sold 1,957 shares of Disc Medicine stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $64.63, for a total transaction of $126,480.91. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Rahul Khara sold 7,500 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $55.54, for a total value of $416,550.00. Following the completion of the sale, the insider now directly owns 14,035 shares of the company’s stock, valued at approximately $779,503.90. This represents a 34.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 85,921 shares of company stock worth $5,389,978 in the last three months. 4.24% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Disc Medicine

Several institutional investors and hedge funds have recently bought and sold shares of IRON. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after purchasing an additional 337 shares in the last quarter. Quest Partners LLC acquired a new position in Disc Medicine in the 3rd quarter valued at approximately $131,000. Quantbot Technologies LP purchased a new stake in Disc Medicine in the 3rd quarter worth approximately $146,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Disc Medicine during the 4th quarter valued at $235,000. Finally, Intech Investment Management LLC purchased a new position in shares of Disc Medicine during the 3rd quarter valued at $228,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.